NASDAQ · Biotechnology

IKT (IKT) Stock

$2.32 -1.49% NASDAQ: IKT Healthcare

Valuation

MetricValue
Price$2.32
Market Cap$305.66M
P/E Ratio-4.46
P/B Ratio1.72
P/S Ratio0.00
EPS (TTM)$-0.38
52-Week High$2.47
52-Week Low$1.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-40.23%
ROA-22.61%
ROCE-30.06%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio22.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$0$0$0$0
Operating Profit$-15.0M$-18.0M$-20.0M$-29.0M$-52.0M
Net Profit$-15.0M$-18.0M$-19.0M$-28.0M$-48.0M
EPS$-4.88$-4.26$-3.57$-1.16$-0.49
Op Margin-476.2%-14686.2%-7712.0%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$42.0M$25.0M$15.0M$99.0M$181.0M
Total Liabilities$4.0M$4.0M$4.0M$4.0M$8.0M
Cash$41.0M$7.0M$9.0M$56.0M$139.0M
Borrowings$0$0$1.0M$0$0

Latest News

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility GlobeNewswire · Jul 14, 2026 Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 Oppenheimer Initiates Inhibikase Therapeutics at Outperform MT Newswires · Jun 10, 2026 Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-17.0M$-18.0M$-19.0M$-28.0M
Investing Cash Flow$0$-16.0M$12.0M$-37.0M$2.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$27.0M$-34.0M$2.0M$47.0M$83.0M
Free Cash Flow$-14.0M$-18.0M$-18.0M$-19.0M$-28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-2.36
FCF Yield-16.17%
Quick Ratio30.14
Interest Coverage—
Return 1Y17.68%
Return 3Y-10.38%
Return 5Y-86.43%

Ownership

Insiders Held5.40%
Institutions Held94.50%
Institutions Float Held99.89%
Institutional HolderSharesReport Date
Sands Capital Alternatives, LLC13,018,9652026-03-31
Soleus Capital Management, L.P.10,875,0002026-03-31
Fairmount Funds Management LLC8,625,0002026-03-31
Trails Edge Capital Partners, LP8,057,3452026-03-31
Adar1 Capital Management, LLC 6,606,5722026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
ATOS $2.36 -2.48% -1.23 $23.54M 0.00%
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
ENTX $2.87 +1.77% -4.96 $141.46M 0.00%
ESLAEstrella Immunopharma, Inc. $0.78 +0.06% -2.25 $33.59M 0.00%

About IKT

IKT is led by CEO Mark T. Iwicki, employs 15 people, headquartered in US, publicly traded since 2020.

IKT stock trades at $2.32 with a market capitalization of $305.66M. The stock is valued at a price-to-earnings (P/E) ratio of -4.46, price-to-book of 1.72, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.33 and $2.47, and currently trades 6.1% below its 52-week high.

On profitability, IKT generates a return on equity (ROE) of -40.23%, return on capital employed of -30.06%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides